AI has applications in many areas of research, including genomics. Slavé Petrovski of AstraZeneca reveals how AI is used in the study of the human genome and how it may evolve in the future.
List view / Grid view
Filter the results
Claus Bendtsen at AstraZeneca reveals how AI can be used to improve our understanding of disease, to help identify the causes of conditions and aid in drug discovery.
A new AI project marks the first time 10 pharmaceutical companies have agreed to share data to aid drug discovery.
A new study has shown that an experimental drug known as AZ32 significantly extends the survival of glioblastoma multiforme, the most common and deadly form of brain cancer...
Advances in genomics and structural biology are providing drug discovery scientists with more biological targets to prosecute, and greater information about each one.
Signs collaboration agreement with AstraZeneca to offer state-of-the-art technology to clients.
A team of researchers from the University of Liverpool and AstraZeneca has made an important contribution to our understanding of cancer cell regulation, holding promise for improved future cancer treatment.
A new race is well underway involving big pharma and big data companies to see who can most effectively mine the new massive data using artificial intelligence (AI). The aim: reducing costs by using targeted in silico analysis, reducing in vitro and in vivo screening, and reviewing huge quantities of…
Mass spectrometry imaging allows direct measurement of the molecular composition of a sample. It can be used to image the spatial distribution of exogenous drugs and endogenous metabolites simultaneously over the surface of tissue sections or small biopsy, allowing new insights into both compound efficacy and safety during drug discovery.
The Medical Research Council has formed partnerships with UCB and AstraZeneca, the deals will help speed translation of discovery research into potential therapies...